The McGill research team, operating out of the Rosalind & Morris Goodman Cancer Institute in collaboration with the McGill University Health Centre’s Research Institute, has unveiled a groundbreaking approach that involves the targeted inhibition of two proteins, PTPN1 and PTPN2. By suppressing these proteins, the researchers have unlocked the ability of NK cells to bypass the tumor’s protective barriers, effectively transforming these immune cells into more aggressive and efficient killers of cancer cells.

Preclinical studies demonstrate that this method markedly amplifies NK cell cytotoxicity against a spectrum of challenging tumors including leukemia, glioblastoma, kidney cancer, and the notoriously difficult to treat triple-negative breast cancer. Animal models treated with this novel therapeutic approach exhibited substantial delay in tumor progression, indicating a promising trajectory toward clinical applicability.

Crucially, this technique offers a safer and more controllable alternative to conventional genetic engineering methods often employed in immunotherapy. Genetic modifications to immune cells, while effective, carry long-term risks and irreversible changes that complicate patient safety. Instead, the McGill team’s strategy deploys small-molecule inhibitors that temporarily enhance NK cell activity without altering their genetic code, allowing for reversible modulation of immune responses and improved safety profiles.

The practicality of this approach is amplified by its reliance on allogeneic NK cells sourced from umbilical cord blood donations. These NK cells are extracted, cultured, and banked at the Cellular Therapy Laboratory, facilitated by leaders Pierre Laneuville and Linda Peltier, enabling immediate availability for treating multiple patients. This off-the-shelf method overcomes the logistical issues and time delays characteristic of autologous cell therapies, which necessitate patient-specific cell harvesting and modification.

This scalable, cost-efficient approach could revolutionize the deployment of immunotherapies by simplifying the manufacturing process and expediting treatment delivery. According to Chu-Han Feng, a research scientist on the team, the reversible enhancement of NK cells’ anti-tumor activities via widely available pharmacological agents circumvents the complexities and expenses linked with personalized cellular therapies.

Among the spectrum of malignancies, acute myeloid leukemia (AML), a particularly aggressive hematological cancer characterized by poor prognosis and limited therapeutic options, stands to benefit notably from this intervention. The team is keen on advancing toward clinical trials targeting AML, pending regulatory approvals and additional funding to validate and optimize the treatment’s efficacy in patients.

The underlying mechanisms by which PTPN1 and PTPN2 inhibition boosts NK cell function involve modulation of critical immunological pathways. By enhancing interleukin-2 (IL-2) signaling, a cytokine integral to NK cell proliferation and activation, while simultaneously mitigating the immunosuppressive effects of transforming growth factor beta 1 (TGF-β1), the treatment reprograms NK cells for heightened responsiveness and sustained cytotoxic action within the hostile tumor microenvironment.

This dual mechanism is especially important because tumors frequently exploit TGF-β1 signaling to suppress immune responses and promote tumor immune escape. The capacity to counteract this immunosuppression while promoting activation via IL-2 sets this strategy apart from existing therapies that typically target only one aspect of NK cell regulation.

The detailed findings of this study, titled “PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGF𝛃1 response,” were published in the April 2026 issue of EMBO Reports. The publication outlines the rigorous experimental framework and provides compelling evidence of the therapeutic promise held by this immunomodulatory approach.

Support for this work was provided by a coalition of funding bodies including the Canadian Institutes of Health Research Foundation, the McGill University Health Centre Foundation, and Genome Canada/Genome Québec, among others. Importantly, the study acknowledges the vital contribution of cord blood donations from volunteer mothers, underscoring the community’s role in advancing cancer immunotherapy research.

The McGill team’s breakthrough represents a major step forward in the quest to harness the immune system’s natural capacities to combat cancer. By offering a safer, faster, and more accessible means to activate NK cells, this approach has the potential to change the landscape of treatment for patients with difficult-to-treat tumors and those who have exhausted conventional options.

With this advancement, the horizon for cancer immunotherapy expands, promising not just incremental improvements but a paradigm shift in how immune-based therapies are developed and deployed. The marriage of biochemical insight and clinical practicality heralds a new chapter in targeted cancer treatments, driven by the power of natural killer cells bolstered through precision pharmacological control.

Subject of Research: Cells
Article Title: PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGF𝛃1 response
News Publication Date: 15-Apr-2026
Web References: http://dx.doi.org/10.1038/s44319-026-00745-0
References: Feng CH et al., Tremblay ML., EMBO Reports, April 2026
Image Credits: McGill University
Keywords: Cancer, Immunotherapy, Natural Killer Cells, PTPN1, PTPN2, IL-2, TGF-β1, Acute Myeloid Leukemia, Small-molecule drugs, Tumor microenvironment

The crux of this breakthrough lies in targeting the interleukin-1 receptor accessory protein (IL1RAP), a cell surface antigen selectively overexpressed on malignant cells but strikingly absent from healthy tissues. By conjugating cytotoxic agents to monoclonal antibodies specifically recognizing IL1RAP, the research team has effectively created a molecular delivery system capable of ferrying lethal payloads exclusively to cancerous cells. This strategy sharply contrasts with conventional chemotherapies, which indiscriminately affect normal and malignant cells alike, frequently leading to debilitating side effects.

Ewing sarcoma, a rare and aggressively metastatic bone cancer predominantly afflicting children and young adults, has notoriously defied conventional therapies, underscoring an urgent need for innovative treatments. Utilizing sophisticated in vivo and in vitro models, the UBC team demonstrated that their IL1RAP-directed ADC not only eradicated established tumor masses but also significantly mitigated metastatic dissemination. Remarkably, the therapeutic benefits extended beyond Ewing sarcoma, exhibiting potent antitumor activity in lymphoma and other malignancies bearing oncogenic fusions such as NTRK gene rearrangements, underscoring the broad applicability of this approach.

The study, published in the prestigious journal Cancer Discovery, represents an international collaboration spanning multiple continents, blending academic expertise with industrial innovation. Pioneering work first identified IL1RAP as a pivotal facilitator of cancer cell survival in the bloodstream, particularly during the metastatic cascade where tumor cells endure oxidative stress, shear forces, and immune surveillance. This protein acts as a protective shield, enabling malignant cells to colonize distant tissues. By turning this adaptive mechanism into a therapeutic vulnerability, the researchers have ushered in a paradigm shift in cancer treatment.

One of the most compelling features of the IL1RAP ADC is its remarkable safety profile observed in extensive preclinical testing. The selective expression of IL1RAP on cancer cells allows for minimized off-target toxicity, a critical barrier that has historically hampered the clinical success of antibody-based therapeutics. The ADC’s design employs an optimized linker-payload system that ensures the cytotoxic agent remains inactive during systemic circulation, unleashing its full potency only upon internalization into IL1RAP-expressing tumor cells.

This advancement draws on prior foundational studies by Dr. Poul Sorensen and collaborators, including lead author Dr. Haifeng Zhang, who elucidated the role of IL1RAP in facilitating metastasis — the process by which cancer spreads and accounts for the majority of cancer-related mortalities worldwide. The ability to impair metastatic competency by selectively targeting IL1RAP-expressing cells is a testament to the therapeutic’s precision and potential clinical impact.

Clinical translation now appears imminent. With comprehensive toxicology and efficacy data providing robust validation, the investigators are poised to embark on early-phase human trials. Such trials will be vital in confirming the ADC’s safety, optimal dosing, and therapeutic window in patients. If successful, this could herald a new era of precision oncology where genetically defined cancers, especially those driven by oncogenic fusions, can be managed more effectively with targeted interventions minimizing collateral damage to patients.

The molecular engineering underpinning this ADC involves sophisticated bioconjugation techniques to ensure stable yet cleavable linkages between the antibody and drug. This is crucial because premature release of the cytotoxin could lead to systemic toxicity, while insufficient payload release inside the tumor cell could render the therapy ineffective. The ADCs harnessed in this study, including proprietary molecules ADV581-DXd and ADV101, were intricately designed and manufactured through industry collaborations with companies such as Advesya and DualityBio, highlighting the fusion of academia and biotech innovation.

Moreover, the therapeutic potential of IL1RAP targeting transcends cancer type. Given its expression in a spectrum of fusion-positive malignancies, the strategy holds promise not only for pediatric oncology but also for adult cancers characterized by oncogenic drivers that have historically been elusive to targeted therapies. In doing so, it addresses a substantial unmet medical need in the oncology community.

Metastasis remains the principal cause of cancer lethality, largely because disseminated tumor cells adapt unique survival mechanisms that evade conventional treatments and immune detection. By co-opting the IL1RAP axis, this ADC design aims to penetrate the metastatic shield and deliver a cytotoxic strike precisely where it counts, interrupting the lethal march of metastatic progression at its roots.

Overall, this initiative exemplifies the power of translational research—bridging molecular discovery to therapeutic innovation. The selective targeting of IL1RAP not only eradicates primary tumors but also strikes at metastatic disease, potentially revolutionizing outcomes for patients who currently face limited therapeutic options.

In conclusion, the development of IL1RAP antibody-drug conjugates reflects a monumental stride forward for the field of targeted cancer therapy. Integrating molecular biology, antibody engineering, drug conjugation chemistry, and preclinical validation, this precision medicine approach could soon translate into life-saving treatments. With human trials on the horizon, the oncology community eagerly anticipates the outcomes that could redefine cancer care for fusion-driven malignancies across the globe.

Subject of Research: Cells

Article Title: IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers

News Publication Date: 13-Apr-2026

Web References:

• Cancer Discovery Article
• DOI Link

Image Credits: Sorensen Lab

Keywords: Cancer treatments, Cancer, Bone cancer, Tumor development, Sarcoma, Metastasis, Oncology, Translational research